Evidence map›Paper›PMID 32088791›Full record

ArticleBiotechnology letters2020

Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.

Wei Chen, Tao Kang, Rongliang Yuan, Congwen Shao, Shenrong Jing

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wei ChenMedical School, Kunming University of Science and Technology, No. 727, Southern Jingming Road, Chenggong District, Kunming, 650500, Yunnan, China.
Tao KangMedical School, Kunming University of Science and Technology, No. 727, Southern Jingming Road, Chenggong District, Kunming, 650500, Yunnan, China.
Rongliang YuanWuxi Huapai Biotechnology Co., Ltd, Wuxi, Jiangsu, China.
Congwen ShaoWuxi Huapai Biotechnology Co., Ltd, Wuxi, Jiangsu, China.
Shenrong JingMedical School, Kunming University of Science and Technology, No. 727, Southern Jingming Road, Chenggong District, Kunming, 650500, Yunnan, China. jingshenrong@kmust.edu.cn.ORCID http://orcid.org/0000-0001-5699-6888
Kunming University of Science and Technology · CN

Funding

the National Natural Science Foundation of China No. 81860357
6 · The paper itself

Abstract

objectivesNoroviruses (NoVs) are major cause of acute viral gastroenteritis in worldwide, and the lack of a cell culture system that must be considered the virus like particles (VLPs) are used as an effective vaccine development. MATERIALS AND

methodsIn the present study, we investigated the expression of the major capsid protein (VP1) of the Genogroup II, genotype 17 (GII.17) NoV, using recombinant baculovirus system in insect cells, as well as a saliva binding blockade assay to detect their protective potency.

resultsOur results showed that GII.17 VLPs could be successfully generated in sf9 insect cells, and electron microscopic revealed that GII.17 VLPs appeared as spherical particles with a - 35 nm diameter. Immunized mice with purified VLPs produced GII.17 specific sera and could efficiently block GII.17 VLPs binding to the saliva histo-blood group antigens (HBGAs).

conclusionsTogether, these results suggested that GII.17 VLPs represent a promising vaccine candidate against NoV GII.17 infection and strongly support further preclinical and clinical studies.

Indexed as

AnimalsAntibodies, ViralBlood Group AntigensCaliciviridae InfectionsDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CNorovirusRabbitsRecombinant ProteinsSalivaSf9 CellsVaccines, Virus-Like ParticleViral Core ProteinsAntibodies, ViralBlood Group AntigensRecombinant ProteinsVaccines, Virus-Like ParticleViral Core ProteinsNorovirus GII.17Saliva histo-blood group antigens (HBGAs)sf9 cellsVaccineVirus like particles (VLPs)

Identifiers

PMID32088791
PMCPMC7223773
OpenAlexW3007968623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.